Integrin αvβ6 is a membrane-spanning heterodimeric glycoprotein involved in wound healing and the pathogenesis of diseases including fibrosis and cancer. Therefore, it is of great clinical interest for us to understand the molecular mechanisms of its biology. As the limiting binding partner in the heterodimer, the β6 subunit controls αvβ6 expression and availability. Here we describe our understanding of the ITGB6 gene encoding the β6 subunit, including its structure, transcriptional and post-transcriptional regulation, the biological effects observed in ITGB6 deficient mice and clinical cases of ITGB6 mutations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gene.2019.100023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrin β6/Annexin A2 axis triggers autophagy to orchestrate hepatocellular carcinoma radioresistance.
Cell Death Differ
November 2024
Center of Hepato-Pancreato-Biliary Surgery, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Radiotherapy (RT) is one of the main therapies for hepatocellular carcinoma (HCC), but its effectiveness has been constrained due to the resistance effect of radiation. Thus, the factors involved in radioresistance are evaluated and the underlying molecular mechanisms are also done. In this present study, we identified Integrin β6 (ITGB6) as a potential radioresistant gene through an integrative analysis of transcriptomic profiles, proteome datasets and survival using HCC cases treated with IR.
View Article and Find Full Text PDFIntegrin subunit beta 6 is a potential diagnostic marker for acute kidney injury in patients with diabetic kidney disease: a single cell sequencing data analysis.
Ren Fail
December 2024
Department of Emergency Medicine, Tianjin Medical University General Hospital, Tianjin, China.
Article Synopsis
- Diabetic kidney disease (DKD) often leads to acute kidney injury (AKI), making it essential to develop strategies to prevent and treat these conditions.
- Researchers analyzed datasets from healthy individuals and patients with AKI and DKD to identify common differentially expressed genes (DEGs) and construct gene interaction networks for further analysis.
- Four key DEGs were highlighted, particularly Integrin Subunit Beta 6, which may serve as a potential biomarker for early AKI diagnosis and a target for therapeutic interventions in DKD patients.
miRNA and mRNA Signatures in Human Acute Kidney Injury Tissue.
Am J Pathol
January 2025
Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana; Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana.
Acute kidney injury (AKI) is an important contributor to the development of chronic kidney disease (CKD). There is a need to understand molecular mediators that drive recovery and progression to CKD. In particular, the regulatory role of miRNAs in AKI is poorly understood.
View Article and Find Full Text PDFpromotes esophageal carcinoma through regulating signaling.
Epigenomics
October 2024
Department of Oncology, The Central Hospital of Yongzhou, Hunan Province, Yongzhou, 425000, China.
To investigate function of somatostatin receptor 5 antisense RNA 1 (SSTR5-AS1) in esophageal carcinoma (ESCA). The cellular function was assessed using EdU staining and Transwell assay. The localization of SSTR5-AS1 was measured using fluorescence hybridization staining.
View Article and Find Full Text PDFITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4 macrophage infiltration.
Nat Commun
August 2024
Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Enoblituzumab, an immunotherapeutic agent targeting CD276, shows both safety and efficacy in activating T cells and oligodendrocyte-like cells against various cancers. Preclinical studies and mouse models suggest that therapies targeting CD276 may outperform PD1/PD-L1 blockade. However, data from mouse models indicate a significant non-responsive population to anti-CD276 treatment, with the mechanisms of resistance still unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!